Monopar files provisional patent for novel radiopharmaceutical linkers and uPAR compositions

Monopar Therapeutics

Filed provisional patent covering a family of linkers connecting radioisotopes to targeting agents, including uPAR antibody MNPR-101.
Claims include composition of matter for linkers and uPAR targeting agents linked with therapeutic radioisotopes.
New linkers designed to enhance stability and biodistribution of Monopar's therapeutic radiopharmaceuticals.
Linker family works with wide range of isotopes and targeting molecules (small molecules/peptides/antibodies).
Management sees potential for licensing and development collaborations with industry partners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.